High blood pressure is the main modifiable risk factor for preventing cardiovascular events in people who have had a stroke or transient ischaemic attack; however, only approximately one in three ...
Intravenous thrombolysis has become a fairly standard therapy for significant early ischemic stroke, with approximately ...
Teleneurological ward rounds appeared to better meet care quality criteria set by guidelines, according to the observational ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. National Institutes of Health Director Jay Bhattacharya promised a House ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The newest rankings of research institutions based on National Institutes of Health funding ...
Please provide your email address to receive an email when new articles are posted on . An investigational stent retriever device was highly effective in restoring blood flow in distal vessel ischemic ...
Abstract: Ischemic stroke is a leading cause of disability and mortality worldwide, requiring early and accurate prediction for timely intervention. This study proposes an XGBoost-based machine ...
The National Institutes of Health (NIH) halted a treatment arm of Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) in a phase 3 stroke prevention trial after an independent committee flagged safety ...
Hello. Good morning and good afternoon, everybody, and welcome to our investor webinar on the results of the OCEANIC-STROKE Phase III trial directly live from ISC 2026 in New Orleans. So my name is ...
NEW ORLEANS -- Factor XIa (FXIa) inhibition for secondary stroke prevention got a major win in the large OCEANIC-STROKE placebo-controlled trial. Among adults with acute non-cardioembolic ischemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results